Taivex’s ‘s T-1101 and T-1201 Invited to Present Study Progress at KSMO 2024 Annual Meeting
Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of Medical Oncology (KSMO) 2024 Annual Meeting. The company will unveil the unique properties of these innovative therapies and their clinical trial designs, highlighting their potential impact on cancer treatment. …